{"corpus_id":11193002,"paper_sha":"adfed30a976ef37b8157df6ca351d3a8f7d5445c","doi":"10.1001/jama.2010.594","arxiv_id":null,"pmid":20460620,"pmcid":null,"mag_id":2171086243,"dblp_id":null,"acl_id":null,"title":"Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial.","year":2010,"publication_date":"2010-05-12","venue":"Journal of the American Medical Association (JAMA)","journal":{"name":"JAMA","pages":"\n          1815-22\n        ","volume":"303 18"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":50,"citation_count":1369,"influential_citation_count":51,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Accidental Falls","mj":false,"qs":[{"q":"prevention & control","mj":true,"ui":"Q000517"}],"ui":"D000058"},{"d":"Administration, Oral","mj":false,"ui":"D000284"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Aged, 80 and over","mj":false,"ui":"D000369"},{"d":"Bone Density Conservation Agents","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D050071"},{"d":"Cholecalciferol","mj":false,"qs":[{"q":"administration & dosage","mj":true,"ui":"Q000008"},{"q":"adverse effects","mj":false,"ui":"Q000009"}],"ui":"D002762"},{"d":"Double-Blind Method","mj":false,"ui":"D004311"},{"d":"Drug Administration Schedule","mj":false,"ui":"D004334"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Fractures, Bone","mj":false,"qs":[{"q":"prevention & control","mj":true,"ui":"Q000517"}],"ui":"D050723"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Risk Factors","mj":false,"ui":"D012307"},{"d":"Seasons","mj":false,"ui":"D012621"},{"d":"Treatment Failure","mj":false,"ui":"D017211"}],"chemicals":[{"n":"Bone Density Conservation Agents","ui":"D050071","reg":"0"},{"n":"Cholecalciferol","ui":"D002762","reg":"1C6V77QF41"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://dro.deakin.edu.au/articles/journal_contribution/Annual_High-Dose_Oral_Vitamin_D_and_Falls_and_Fractures_in_Older_Women/20860144/2/files/37122502.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/adfed30a976ef37b8157df6ca351d3a8f7d5445c","s2_open_access_license":"other-oa","s2_open_access_status":"GREEN","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"CONTEXT: Improving vitamin D status may be an important modifiable risk factor to reduce falls and fractures; however, adherence to daily supplementation is typically poor. OBJECTIVE: To determine whether a single annual dose of 500,000 IU of cholecalciferol administered orally to older women in autumn or winter would improve adherence and reduce the risk of falls and fracture. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, placebo-controlled trial of 2256 community-dwelling women, aged 70 years or older, considered to be at high risk of fracture were recruited from June 2003 to June 2005 and were randomly assigned to receive cholecalciferol or placebo each autumn to winter for 3 to 5 years. The study concluded in 2008. INTERVENTION: 500,000 IU of cholecalciferol or placebo. MAIN OUTCOME MEASURES: Falls and fractures were ascertained using monthly calendars; details were confirmed by telephone interview. Fractures were radiologically confirmed. In a substudy, 137 randomly selected participants underwent serial blood sampling for 25-hydroxycholecalciferol and parathyroid hormone levels. RESULTS: Women in the cholecalciferol (vitamin D) group had 171 fractures vs 135 in the placebo group; 837 women in the vitamin D group fell 2892 times (rate, 83.4 per 100 person-years) while 769 women in the placebo group fell 2512 times (rate, 72.7 per 100 person-years; incidence rate ratio [RR], 1.15; 95% confidence interval [CI], 1.02-1.30; P = .03). The incidence RR for fracture in the vitamin D group was 1.26 (95% CI, 1.00-1.59; P = .047) vs the placebo group (rates per 100 person-years, 4.9 vitamin D vs 3.9 placebo). A temporal pattern was observed in a post hoc analysis of falls. The incidence RR of falling in the vitamin D group vs the placebo group was 1.31 in the first 3 months after dosing and 1.13 during the following 9 months (test for homogeneity; P = .02). In the substudy, the median baseline serum 25-hydroxycholecalciferol was 49 nmol/L. Less than 3% of the substudy participants had 25-hydroxycholecalciferol levels lower than 25 nmol/L. In the vitamin D group, 25-hydroxycholecalciferol levels increased at 1 month after dosing to approximately 120 nmol/L, were approximately 90 nmol/L at 3 months, and remained higher than the placebo group 12 months after dosing. CONCLUSION: Among older community-dwelling women, annual oral administration of high-dose cholecalciferol resulted in an increased risk of falls and fractures. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12605000658617; isrctn.org Identifier: ISRCTN83409867.","claims":[{"public_id":"cl_e7525d748e2dfd2249a95d0eb17d04d2","status":"active","text":"A substudy showed that serum 25-hydroxycholecalciferol rose sharply after dosing and remained higher than placebo for 12 months.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_e7525d748e2dfd2249a95d0eb17d04d2"},{"public_id":"cl_e7352fbb28872afbbeab1c4e9d04a8f6","status":"active","text":"Annual oral administration of 500,000 IU cholecalciferol increased the risk of falls among older community-dwelling women at high risk of fracture.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_e7352fbb28872afbbeab1c4e9d04a8f6"},{"public_id":"cl_a5c56d0d0eabfd1b9e74d3f79c0c3e86","status":"active","text":"Annual oral administration of 500,000 IU cholecalciferol increased the risk of fractures compared with placebo.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a5c56d0d0eabfd1b9e74d3f79c0c3e86"},{"public_id":"cl_0927abe09f8ed7e51dda46e5cd82ff99","status":"active","text":"The excess fall risk was greatest in the first 3 months after dosing and was smaller during the following 9 months.","confidence":0.92,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_0927abe09f8ed7e51dda46e5cd82ff99"}],"concepts":[{"public_id":"co_139f3d26023b929804d4deafdf217c31","status":"active","name":"25-hydroxycholecalciferol","description":"The circulating metabolite of vitamin D measured in the blood substudy.","types":["biomarker","analyte"],"aliases":["25-hydroxyvitamin D"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_139f3d26023b929804d4deafdf217c31"},{"public_id":"co_181bb23bbe836e9de724e6b8b74a9859","status":"active","name":"older community-dwelling women","description":"Women aged 70 years or older living in the community and enrolled as trial participants.","types":["population"],"aliases":["older women"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_181bb23bbe836e9de724e6b8b74a9859"},{"public_id":"co_39ef8c325382cfc43e6c24c561cf536e","status":"active","name":"annual high-dose oral vitamin D","description":"A yearly oral supplementation strategy using a very large dose of vitamin D given in autumn or winter.","types":["intervention","treatment regimen"],"aliases":["annual oral administration of high-dose cholecalciferol","high-dose oral cholecalciferol"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_39ef8c325382cfc43e6c24c561cf536e"},{"public_id":"co_6423143b1102d047827560e8a02ae769","status":"active","name":"parathyroid hormone","description":"A hormone measured alongside vitamin D metabolites in the blood substudy.","types":["biomarker","analyte"],"aliases":["PTH"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6423143b1102d047827560e8a02ae769"},{"public_id":"co_6a7db0c9a1b1a2fd4e1c1b7f3821735d","status":"active","name":"placebo","description":"An inactive comparison treatment used in the randomized controlled trial.","types":["control","placebo"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6a7db0c9a1b1a2fd4e1c1b7f3821735d"},{"public_id":"co_a0c991c4f92d50b1524e71c9eabfb08f","status":"active","name":"substudy","description":"A nested blood-sampling component with serial measurements in a randomly selected subset of participants.","types":["study component"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a0c991c4f92d50b1524e71c9eabfb08f"},{"public_id":"co_ac991f9d885cdb1d920e1f517ae81699","status":"active","name":"falls","description":"Occurrences of participants falling, recorded as a clinical outcome in the trial.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ac991f9d885cdb1d920e1f517ae81699"},{"public_id":"co_e17369ae4ef7f47e608bf0305d1c69f2","status":"active","name":"fractures","description":"Bone fracture events confirmed radiologically and used as a clinical outcome.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e17369ae4ef7f47e608bf0305d1c69f2"},{"public_id":"co_eab043a1559899ea5d0c0165fabaeb88","status":"active","name":"post hoc analysis","description":"An additional analysis conducted after the main trial results to examine timing patterns in falls.","types":["analysis"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_eab043a1559899ea5d0c0165fabaeb88"},{"public_id":"co_edf189a9c8ef9857c27b593bb70080a6","status":"active","name":"cholecalciferol","description":"Vitamin D3 administered orally in the trial intervention.","types":["compound","intervention"],"aliases":["vitamin D"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_edf189a9c8ef9857c27b593bb70080a6"}],"external_ids":{"DOI":"10.1001/jama.2010.594","ArXiv":null,"PubMed":20460620,"PubMedCentral":null,"MAG":2171086243,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://dro.deakin.edu.au/articles/journal_contribution/Annual_High-Dose_Oral_Vitamin_D_and_Falls_and_Fractures_in_Older_Women/20860144/2/files/37122502.pdf","landing_url":"https://www.semanticscholar.org/paper/adfed30a976ef37b8157df6ca351d3a8f7d5445c","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"other-oa","status":"GREEN","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631248,"paper_uid":"882e9e11-3a0f-4dc4-a5e4-eb2da3f88865","canonical_identity":{"paper_id":631248,"paper_uid":"882e9e11-3a0f-4dc4-a5e4-eb2da3f88865","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/11193002"}